Top

Published in:

01-04-2012 | Research

Brevican, Neurocan, Tenascin-C and Versican are Mainly Responsible for the Invasiveness of Low-Grade Astrocytoma

Authors: Imre Varga, Gábor Hutóczki, Csaba D. Szemcsák, Gábor Zahuczky, Judit Tóth, Zsolt Adamecz, Annamária Kenyeres, László Bognár, Zoltán Hanzély, Almos Klekner

Published in: Pathology & Oncology Research | Issue 2/2012

Abstract

The extent of tumor removal determines the effectiveness of postoperative oncotherapy. This is especially true for primary brain tumors, where peritumoral invasion usually makes radical resection impossible. The aim of the study was to determinate the specific expression pattern of invasion related molecules of different intracranial tumors and to identify molecules that are principally responsible for the peritumoral invasiveness of grade II astrocytoma mRNA expression of 26 extracellular matrix (ECM) molecules was determined in tissue samples from grade II astrocytoma, schwannoma, intracerebral metastases of non-small cell lung cancer and normal brain. Immunohistochemical staining for brevican, neurocan, tenascin-C and versican was also performed for each tumor group. Comparing astrocytoma to metastasis, schwannoma and normal brain; and metastasis and schwannoma to normal brain, 22, 17, 20, 21, and 19 molecules, respectively, were found to be significantly overexpressed at the mRNA level. Cluster analysis of mRNA expression showed a specific gene expression pattern for each histological group. Four molecules of 26 were found to be associated to astrocytoma. Immunohistochemical staining confirmed the results of the mRNA analysis at the protein level. Tumors of different origin have a specific invasive phenotype that can evidently determinate on gene expression level. This characteristic expression pattern of the invasion-related molecules might help to screen exact targets for anti-invasion drugs. In case of low-grade astrocytoma. brevican, neurocan, tenascin-C and versican were found to correlate principally with the invasive phenotype of low-grade astrocytoma, thus these molecules can potentially serve as targets for anti-invasion therapy in the future.

Klekner A, Varga I, Bognár L et al (2010) Extracellular matrix of cerebral tumors with different invasiveness. Ideggyogy Sz 63(1–2):38–43 (Hu)PubMed

Varga I, Hutóczki G, Petrás M et al (2010) Expression of invasion-related extracellular matrix molecules in human glioblastoma versus intracerebral lung adenocarcinoma metastasis. Cen Eur Neurosurg 71(4):173–180PubMedCrossRef

Kyoshima K, Akaishi K, Tokushige K et al (2004) Surgical experience with resection en bloc of intramedullary astrocytomas and ependymomas in the cervical and cervicothoracic region. J Clin Neurosci 11(6):623–628PubMedCrossRef

Ramina R, Coelho Neto M, Fernandes YB et al (2005) Intrinsic tectal low grade astrocytomas: is surgical removal an alternative treatment? Long-term outcome of eight cases. Arq Neuropsiquiatr 63(1):40–45PubMedCrossRef

Abacioglu U, Caglar H, Atasoy BM et al (2010) Gamma knife radiosurgery in non small cell lung cancer patients with brain metastases: treatment results and prognostic factors. J BUON 15(2):274–280PubMed

Catinella FP, Kittle CF, Faber LP et al (1989) Surgical treatment of primary lung cancer and solitary intracranial metastasis. Chest 136(5 Suppl):e30

Okada Y (2000) Tumor cell-matrix interaction: pericellular matrix degradation and metastasis. Verh Dtsch Ges Pathol 84:33–42PubMed

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408PubMedCrossRef

Han S, Sidell N, Roman J (2005) Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase. Canc Lett 219(1):71–81CrossRef

10.

Hirose J, Kawashima H, Yoshie O et al (2001) Versican interacts with chemokines and modulates cellular responses. J Biol Chem 276(7):5228–5234PubMedCrossRef

11.

Sainte-Marie G (1962) A paraffin embedding technique for studies employing immunofluorescence. J Histochem Cytochem 10:250–256CrossRef

12.

Tuckett F, Morriss-Kay G (1988) Alcian blue staining of glycosaminoglycans in embryonic material: effect of different fixatives. Histochem J 20:174–182PubMedCrossRef

13.

Kono K, Inoue Y, Nakayama K et al (2001) The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 22(6):1081–1088PubMed

14.

Lu S, Ahn D, Johnson G et al (2004) Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema: introduction of the tumor infiltration index. Radiology 232(1):221–228PubMedCrossRef

15.

Miklós P, Gábor H, Imre V et al (2009) Expression pattern of invasion-related molecules in brain tumors of different origin. Magy Onkol 53(3):253–258 (Hu)CrossRef

16.

Wang W, Steward CE, Desmond PM (2009) Diffusion tensor imaging in glioblastoma multiforme and brain metastases: the role of p, q, L, and fractional anisotropy. AJNR Am J Neuroradiol 30(1):203–208PubMedCrossRef

17.

Lo CK, Yu CH, Ma CC et al (2010) Surgical management of primary non-small-cell carcinoma of lung with synchronous solitary brain metastasis: local experience. Hong Kong Med J 16(3):186–191PubMed

18.

Pfannschmidt J, Dienemann H (2010) Surgical treatment of oligometastatic non-small cell lung cancer. Lung Canc 69(3):251–258CrossRef

19.

Hu B, Kong LL, Matthews RT et al (2008) The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. J Biol Chem 283(36):24848–24859PubMedCrossRef

20.

Viapiano MS, Bi WL, Piepmeier J et al (2005) Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Canc Res 65(15):6726–6733CrossRef

21.

Viapiano MS, Hockfield S, Matthews RT (2008) BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion. J Neurooncol 88(3):261–272PubMedCrossRef

22.

Viapiano MS, Matthews RT, Hockfield S (2003) A novel membrane-associated glycovariant of BEHAB/brevican is up-regulated during rat brain development and in a rat model of invasive glioma. J Biol Chem 278(35):33239–33247PubMedCrossRef

23.

Nutt CL, Matthews RT, Hockfield S (2001) Glial tumor invasion: a role for the upregulation and cleavage of BEHAB/brevican. Neuroscientist 7(2):113–122PubMedCrossRef

24.

Gary SC, Hockfield S (2000) BEHAB/brevican: an extracellular matrix component associated with invasive glioma. Clin Neurosurg 47:72–82PubMed

25.

Gary SC, Kelly GM, Hockfield S (1998) BEHAB/brevican: a brain-specific lectican implicated in gliomas and glial cell motility. Curr Opin Neurobiol 8(5):576–581PubMedCrossRef

26.

Gary SC, Zerillo CA, Chiang VL et al (2000) cDNA cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma. Gene 256(1–2):139–147PubMedCrossRef

27.

Talts U, Kuhn U, Roos G et al (2000) Modulation of extracellular matrix adhesiveness by neurocan and identification of its molecular basis. Exp Cell Res 259(2):378–388PubMedCrossRef

28.

Akita K, Toda M, Hosoki Y et al (2004) Heparan sulphate proteoglycans interact with neurocan and promote neurite outgrowth from cerebellar granule cells. Biochem J 383(Pt 1):129–138PubMed

29.

Rauch U, Feng K, Zhou XH (2001) Neurocan: a brain chondroitin sulfate proteoglycan. Cell Mol Life Sci 58(12–13):1842–1856PubMedCrossRef

30.

Zinovieva E, Lebrun N, Letourneur F et al (2008) Lack of association between Tenascin-C gene and spondyloarthritis. Rheumatology (Oxford) 47(11):1655–1658CrossRef

31.

Meloty-Kapella CV, Degen M, Chiquet-Ehrismann R et al (2006) Avian tenascin-W: expression in smooth muscle and bone, and effects on calvarial cell spreading and adhesion in vitro. Dev Dyn 235(6):1532–1542PubMedCrossRef

32.

Pajala A, Melkko J, Leppilahti J et al (2009) Tenascin-C and type I and III collagen expression in total Achilles tendon rupture. Histol Histopathol 24(10):1207–1211PubMed

33.

Engel J (1989) EGF-like domains in extracellular matrix proteins: localized signals for growth and differentiation? FEBS Lett 251(1–2):1–7PubMedCrossRef

34.

Swindle CS, Tran KT, Johnson TD et al (2001) Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol 154(2):459–468PubMedCrossRef

35.

Fischer D, Brown-Lüdi M, Schulthess T et al (1997) Concerted action of tenascin-C domains in cell adhesion, anti-adhesion and promotion of neurite outgrowth. J Cell Sci 110(Pt 13):1513–1522PubMed

36.

Hirata E, Arakawa Y, Shirahata M et al (2009) Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Canc Sci 100(8):1451–1459CrossRef

37.

Maris C, Rorive S, Sandras F et al (2008) Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas. Neuropathol Appl Neurobiol 34(3):316–329PubMedCrossRef

38.

Bicer A, Guclu B, Ozkan A et al (2010) Expressions of angiogenesis associated matrix metalloproteinases and extracellular matrix proteins in cerebral vascular malformations. J Clin Neurosci 17(2):232–236PubMedCrossRef

39.

Kim CH, Bak KH, Kim YS et al (2000) Expression of tenascin-C in astrocytic tumors: its relevance to proliferation and angiogenesis. Surg Neurol 54(3):235–240PubMedCrossRef

40.

Leins A, Riva P, Lindstedt R et al (2003) Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98(11):2430–2439PubMedCrossRef

41.

Zagzag D, Capo V (2002) Angiogenesis in the central nervous system: a role for vascular endothelial growth factor/vascular permeability factor and tenascin-C. Common molecular effectors in cerebral neoplastic and non-neoplastic “angiogenic diseases”. Histol Histopathol 17(1):301–321PubMed

42.

Mukaratirwa S, Chimonyo M, Obwolo M et al (2004) Stromal cells and extracellular matrix components in spontaneous canine transmissible venereal tumour at different stages of growth. Histol Histopathol 19(4):1117–1123PubMed

43.

Xiang YY, Dong H, Wan Y et al (2006) Versican G3 domain regulates neurite growth and synaptic transmission of hippocampal neurons by activation of epidermal growth factor receptor. J Biol Chem 281(28):19358–19368PubMedCrossRef

44.

Wu Y, Sheng W, Chen L et al (2004) Versican V1 isoform induces neuronal differentiation and promotes neurite outgrowth. Mol Biol Cell 15(5):2093–2104PubMedCrossRef

45.

Ricciardelli C, Sakko AJ, Ween MP et al (2009) The biological role and regulation of versican levels in cancer. Canc Metastasis Rev 28(1–2):233–245CrossRef

46.

Wu Y, Zhang Y, Cao L et al (2001) Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding. J Biol Chem 276(17):14178–14186PubMed

47.

Zheng PS, Wen J, Ang LC et al (2004) Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 18(6):754–756PubMed

48.

Soltermann A, Tischler V, Arbogast S (2008) Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Canc Res 14(22):7430–7437CrossRef

49.

Pirinen R, Leinonen T, Böhm J et al (2005) Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol 36(1):44–50PubMedCrossRef

Title: Brevican, Neurocan, Tenascin-C and Versican are Mainly Responsible for the Invasiveness of Low-Grade Astrocytoma
Authors: Imre Varga
Gábor Hutóczki
Csaba D. Szemcsák
Gábor Zahuczky
Judit Tóth
Zsolt Adamecz
Annamária Kenyeres
László Bognár
Zoltán Hanzély
Almos Klekner
Publication date: 01-04-2012
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-011-9461-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

p53 Binds to Estrogen Receptor 1 Promoter in Human Breast Cancer Cells

Prognostic Value of Matrix Metalloproteinase-1/ Proteinase-Activated Receptor-1 Signaling Axis in Hepatocellular Carcinoma

Recombinant Human Endostatin Endostar Inhibits Tumor Growth and Metastasis in a Mouse Xenograft Model of Colon Cancer

High-mobility Group Box 1 is Associated with Clinicopathologic Features in Patients with Hepatocellular Carcinoma

Modern Trends into the Epidemiology and Screening of Ovarian Cancer. Genetic Substrate of the Sporadic Form

Down-Regulated Expression of HSP70 in Correlation with Clinicopathology of Cholangiocarcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer